Short answer
Inmune Bio, Inc. (INMB) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$1M
- +94.8% YoY · +76.5% QoQ
- EPS (diluted)
- −$0.05
- +95.3% YoY · +75.0% QoQ
Source: XBRL data from the Inmune Bio, Inc. (INMB) Q2 2026 10-Q on SEC EDGAR. USD.
Inmune Bio, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0 vs $0 YoY
- Net loss $1.3M vs $24.5M; operating loss $1.5M vs $24.6M
- R&D benefit $0.8M vs $5.8M expense; CORDStrom/INKmune costs $2.5M vs $1.1M
- Cash $18.4M at June 30 vs $24.8M at December 31; operating cash use $6.6M vs $14.2M YoY
- MAA targeted UK by Q3 or early Q4 2026; going-concern doubt and expected future losses disclosed
Risk Factors
- No risk-factors section provided in the submitted excerpt
- No disclosed new, updated, regulatory, operational, competitive, or financial risks in the available text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Inmune Bio, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.